ARGX
argenx SE
Price Chart
Latest Quote
$882.75
+20.58 (+2.39%)
Current Price
| Previous Close | $862.18 |
| Open | $879.95 |
| Day High | $887.35 |
| Day Low | $874.48 |
| Volume | 52,414 |
Stock Information
| Shares Outstanding | 62.19M |
| Total Debt | $47.16M |
| Cash Equivalents | $4.44B |
| Revenue | $4.74B |
| Net Income | $1.49B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $55.84B |
| P/E Ratio | 39.69 |
| EPS (TTM) | $22.51 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.38T |
| Sales | $4.74B |
| Income | $1.49B |
| Book/sh | $4.73 |
| Cash/sh | $71.40 |
| Employees | 2K |
Financial Ratios
| Debt/Eq | 0.64 |
| EPS Growth TTM | 116.00% |
Returns & Margins
| Gross Margin | 58.11% |
| Operating Margin | 30.01% |
| Profit Margin | 31.40% |
Ownership
| Insider Ownership | 0.00% |
| Institutional Ownership | 47.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 24.36 |
| PEG | 1.50 |
| P/S | 11.77 |
| P/B | 188.77 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $1028.52 |
Technical Indicators
| SMA20 | $835.49 |
| SMA50 | $812.92 |
| SMA200 | $807.77 |
| RSI | 68.75 |
| ATR | 27.1255 |
| Shares Float | 1.55B |
| Short Float | 2.91% |
| Short Ratio | 5.58 |
| Volatility | -0.03 |
| Rel Volume | 1.03 |
Performance History
| Week | +0.25% |
| Month | +11.31% |
| Quarter | +27.56% |
| 6 Months | +0.38% |
| YTD | +6.37% |
| Year | +55.41% |
| 3 Years | +127.70% |
| 5 Years | +243.27% |
| 10 Years | +3784.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $893.52 | 333,200 |
| 2026-06-11 | $898.94 | 357,400 |
| 2026-06-10 | $862.18 | 349,300 |
| 2026-06-09 | $884.00 | 304,700 |
| 2026-06-08 | $882.41 | 484,400 |
| 2026-06-05 | $891.32 | 795,700 |
| 2026-06-04 | $842.27 | 228,900 |
| 2026-06-03 | $813.14 | 314,400 |
| 2026-06-02 | $802.17 | 359,200 |
| 2026-06-01 | $836.09 | 252,100 |
| 2026-05-29 | $835.99 | 192,500 |
| 2026-05-28 | $838.49 | 230,100 |
| 2026-05-27 | $820.63 | 204,400 |
| 2026-05-26 | $808.43 | 167,900 |
| 2026-05-22 | $806.46 | 171,200 |
| 2026-05-21 | $816.22 | 429,800 |
| 2026-05-20 | $804.25 | 401,100 |
| 2026-05-19 | $797.77 | 290,900 |
| 2026-05-18 | $776.26 | 306,700 |
| 2026-05-15 | $799.32 | 326,400 |
| 2026-05-14 | $822.13 | 197,200 |
| 2026-05-13 | $802.70 | 381,600 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, SjÃļgren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
đ° Latest News
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
MarketBeat âĸ 2026-06-12T11:06:17Z
European Equities Traded in US as ADRs Rise in Thursday Trading
MT Newswires âĸ 2026-06-11T15:09:49ZAssessing argenx (ENXTBR:ARGX) Valuation After Strong Recent Share Price Momentum
Simply Wall St. âĸ 2026-06-11T03:16:12Z
Sanofi, An Argenx Rival, Bites The Dust â But A Third Biotech Took The Biggest Hit
Investor's Business Daily âĸ 2026-06-10T20:48:19Z
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
Zacks âĸ 2026-06-10T13:17:00Z
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
Zacks âĸ 2026-06-10T12:09:00Z
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Zacks âĸ 2026-06-08T15:40:02Z
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-08T12:56:00Z
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week
MT Newswires âĸ 2026-06-05T15:06:40Zargenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
MarketBeat âĸ 2026-06-05T10:02:23Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $429,642,000 | $212,911,000 | $8,894,000 | $29,431,000 |
| Cost Of Revenue | $450,665,000 | $227,289,000 | $117,835,000 | $29,431,000 |
| Total Revenue | $4,153,482,000 | $2,190,231,000 | $1,226,316,000 | $410,746,000 |
| Operating Revenue | $4,151,316,000 | $2,185,883,000 | $1,190,783,000 | $410,746,000 |
| Expenses | ||||
| Interest Expense | $4,082,000 | $2,464,000 | $906,000 | $2,193,000 |
| Total Expenses | $3,098,867,000 | $2,208,075,000 | $1,646,954,000 | $1,134,665,000 |
| Rent Expense Supplemental | $16,035,000 | $20,888,000 | $11,264,000 | $9,627,000 |
| Other Income Expense | $64,983,000 | $-52,021,000 | $9,662,000 | $-27,942,000 |
| Net Non Operating Interest Income Expense | $159,009,000 | $155,045,000 | $106,480,000 | $22,548,000 |
| Interest Expense Non Operating | $4,082,000 | $2,464,000 | $906,000 | $2,193,000 |
| Operating Expense | $2,648,202,000 | $1,980,786,000 | $1,529,119,000 | $1,105,234,000 |
| Other Operating Expenses | $-82,987,000 | $-57,974,000 | $-42,278,000 | $-30,264,000 |
| Selling And Marketing Expense | $429,192,000 | $326,682,000 | $212,502,000 | $115,950,000 |
| General And Administrative Expense | $930,786,000 | $725,506,000 | $497,037,000 | $353,971,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Net Interest Income | $159,009,000 | $155,045,000 | $106,480,000 | $22,548,000 |
| Interest Income | $163,091,000 | $157,509,000 | $107,386,000 | $24,741,000 |
| Normalized Income | $1,230,910,330 | $868,097,830 | $-308,689,570 | $-683,066,221 |
| Net Income From Continuing And Discontinued Operation | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Total Operating Income As Reported | $1,053,806,000 | $-21,654,000 | $-425,049,000 | $-720,341,000 |
| Net Income Common Stockholders | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Net Income | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Net Income Including Noncontrolling Interests | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Net Income Continuous Operations | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Pretax Income | $1,278,607,000 | $85,180,000 | $-304,496,000 | $-729,314,000 |
| Earnings From Equity Interest | $-12,390,000 | $-7,644,000 | $-4,411,000 | $-677,000 |
| Interest Income Non Operating | $163,091,000 | $157,509,000 | $107,386,000 | $24,741,000 |
| Operating Income | $1,054,615,000 | $-17,844,000 | $-420,638,000 | $-723,919,000 |
| Depreciation Amortization Depletion Income Statement | $7,079,000 | $3,149,000 | $2,366,000 | $2,211,000 |
| Depreciation And Amortization In Income Statement | $7,079,000 | $3,149,000 | $2,366,000 | $2,211,000 |
| Gross Profit | $3,702,817,000 | $1,962,942,000 | $1,108,481,000 | $381,315,000 |
| Per Share | ||||
| Diluted EPS | $19.57 | $12.78 | $-5.16 | $-13.05 |
| Basic EPS | $21.08 | $13.92 | $-5.16 | $-13.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $16,248,330 | $-9,319,170 | $436,430 | $-737,221 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,233,418,000 | $149,548,000 | $-206,356,000 | $-595,514,000 |
| Total Unusual Items | $77,373,000 | $-44,377,000 | $14,073,000 | $-27,265,000 |
| Total Unusual Items Excluding Goodwill | $77,373,000 | $-44,377,000 | $14,073,000 | $-27,265,000 |
| Reconciled Depreciation | $28,102,000 | $17,527,000 | $111,307,000 | $104,342,000 |
| EBITDA (Bullshit earnings) | $1,310,791,000 | $105,171,000 | $-192,283,000 | $-622,779,000 |
| EBIT | $1,282,689,000 | $87,644,000 | $-303,590,000 | $-727,121,000 |
| Diluted Average Shares | $66,029,215 | $65,177,815 | $57,169,253 | $54,381,371 |
| Basic Average Shares | $61,295,149 | $59,855,585 | $57,169,253 | $54,381,371 |
| Diluted NI Availto Com Stockholders | $1,292,035,000 | $833,040,000 | $-295,053,000 | $-709,594,000 |
| Tax Provision | $-13,428,000 | $-747,860,000 | $-9,443,000 | $-19,720,000 |
| Gain On Sale Of Security | $77,373,000 | $-44,377,000 | $14,073,000 | $-27,265,000 |
| Research And Development | $1,364,132,000 | $983,423,000 | $859,492,000 | $663,366,000 |
| Selling General And Administration | $1,359,978,000 | $1,052,188,000 | $709,539,000 | $469,921,000 |
| Other Gand A | $414,221,000 | $279,702,000 | $182,740,000 | $109,604,000 |
| Rent And Landing Fees | $16,035,000 | $20,888,000 | $11,264,000 | $9,627,000 |
| Salaries And Wages | $500,530,000 | $424,916,000 | $303,033,000 | $234,740,000 |
| Other Taxes | - | - | - | $-28,078,000 |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,050,989,000 | $5,316,838,000 | $3,972,279,000 | $2,638,798,000 |
| Total Assets | $8,682,698,000 | $6,202,522,000 | $4,542,458,000 | $3,134,261,000 |
| Total Non Current Assets | $1,783,594,000 | $1,319,419,000 | $418,721,000 | $360,064,000 |
| Other Non Current Assets | $4,838,000 | $1,963,000 | $2,418,000 | $1,737,000 |
| Non Current Prepaid Assets | $25,811,000 | $23,643,000 | $47,327,000 | $0 |
| Non Current Deferred Assets | $1,295,853,000 | $924,299,000 | $97,211,000 | $79,222,000 |
| Non Current Deferred Taxes Assets | $1,295,853,000 | $924,299,000 | $97,211,000 | $79,222,000 |
| Non Current Accounts Receivable | $86,212,000 | $94,854,000 | $76,706,000 | $47,488,000 |
| Investmentin Financial Assets | $47,152,000 | $40,429,000 | $37,243,000 | $39,158,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $37,130,000 | $25,549,000 | $21,715,000 | $21,715,000 |
| Goodwill And Other Intangible Assets | $272,103,000 | $181,445,000 | $125,228,000 | $174,901,000 |
| Other Intangible Assets | $272,103,000 | $181,445,000 | $125,228,000 | $174,901,000 |
| Current Assets | $6,899,104,000 | $4,883,103,000 | $4,123,737,000 | $2,774,197,000 |
| Prepaid Assets | $328,476,000 | $187,948,000 | $134,072,000 | $76,022,000 |
| Inventory | $473,530,000 | $407,233,000 | $310,550,000 | $228,353,000 |
| Receivables | $1,657,059,000 | $909,096,000 | $499,271,000 | $277,275,000 |
| Other Receivables | $10,831,000 | $10,289,000 | $4,546,000 | $2,603,000 |
| Taxes Receivable | $123,123,000 | $40,886,000 | $63,605,000 | $20,526,000 |
| Accrued Interest Receivable | $33,533,000 | $40,214,000 | $13,126,000 | $12,918,000 |
| Accounts Receivable | $1,489,572,000 | $817,707,000 | $417,994,000 | $241,228,000 |
| Cash Cash Equivalents And Short Term Investments | $4,440,039,000 | $3,378,826,000 | $3,179,844,000 | $2,192,548,000 |
| Cash And Cash Equivalents | $3,491,289,000 | $1,499,936,000 | $2,048,844,000 | $800,740,000 |
| Cash Equivalents | $2,541,112,000 | $1,394,409,000 | $1,678,100,000 | $669,147,000 |
| Cash Financial | $950,177,000 | $105,527,000 | $370,744,000 | $131,593,000 |
| Other Current Assets | - | - | - | $-1,000 |
| Debt | ||||
| Total Debt | $47,160,000 | $39,053,000 | $20,000,000 | $12,426,000 |
| Long Term Debt And Capital Lease Obligation | $36,327,000 | $32,520,000 | $15,354,000 | $9,009,000 |
| Current Debt And Capital Lease Obligation | $10,833,000 | $6,533,000 | $4,646,000 | $3,417,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,359,606,000 | $704,239,000 | $444,951,000 | $320,562,000 |
| Total Non Current Liabilities Net Minority Interest | $39,420,000 | $34,323,000 | $21,958,000 | $18,285,000 |
| Non Current Deferred Liabilities | $0 | $0 | $5,155,000 | $8,406,000 |
| Non Current Deferred Taxes Liabilities | $0 | $0 | $5,155,000 | $8,406,000 |
| Current Liabilities | $1,320,186,000 | $669,916,000 | $422,993,000 | $302,277,000 |
| Payables And Accrued Expenses | $694,977,000 | $372,091,000 | $267,455,000 | $195,044,000 |
| Payables | $694,977,000 | $372,091,000 | $267,455,000 | $195,044,000 |
| Other Payable | $98,500,000 | $16,473,000 | $17,564,000 | $3,142,000 |
| Total Tax Payable | $42,209,000 | $13,390,000 | $4,334,000 | $3,181,000 |
| Accounts Payable | $554,268,000 | $342,228,000 | $245,557,000 | $188,721,000 |
| Other Non Current Liabilities | - | - | - | $-1,000 |
| Other Current Liabilities | - | - | - | $1,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $7,323,092,000 | $5,498,283,000 | $4,097,507,000 | $2,813,699,000 |
| Total Equity Gross Minority Interest | $7,323,092,000 | $5,498,283,000 | $4,097,507,000 | $2,813,699,000 |
| Stockholders Equity | $7,323,092,000 | $5,498,283,000 | $4,097,507,000 | $2,813,699,000 |
| Other Equity Interest | $1,335,360,000 | $1,047,231,000 | $771,725,000 | $535,247,000 |
| Gains Losses Not Affecting Retained Earnings | $73,593,000 | $66,713,000 | $72,071,000 | $71,723,000 |
| Retained Earnings | $-279,769,000 | $-1,571,804,000 | $-2,404,844,000 | $-2,109,791,000 |
| Long Term Equity Investment | $3,378,000 | $9,268,000 | $9,912,000 | $1,323,000 |
| Other Equity Adjustments | - | - | - | $477,691,000 |
| Other | ||||
| Ordinary Shares Number | $61,883,306 | $60,760,957 | $59,194,488 | $55,395,856 |
| Share Issued | $61,883,306 | $60,760,957 | $59,194,488 | $55,395,856 |
| Tangible Book Value | $7,050,989,000 | $5,316,838,000 | $3,972,279,000 | $2,638,798,000 |
| Invested Capital | $7,323,092,000 | $5,498,283,000 | $4,097,507,000 | $2,813,699,000 |
| Working Capital | $5,578,918,000 | $4,213,187,000 | $3,700,744,000 | $2,471,920,000 |
| Capital Lease Obligations | $47,160,000 | $39,053,000 | $20,000,000 | $12,426,000 |
| Total Capitalization | $7,323,092,000 | $5,498,283,000 | $4,097,507,000 | $2,813,699,000 |
| Foreign Currency Translation Adjustments | $138,570,000 | $126,832,000 | $131,543,000 | $129,280,000 |
| Unrealized Gain Loss | $-64,977,000 | $-60,119,000 | $-59,472,000 | $-57,557,000 |
| Additional Paid In Capital | $6,186,554,000 | $5,948,916,000 | $5,651,497,000 | $4,309,880,000 |
| Capital Stock | $7,354,000 | $7,227,000 | $7,058,000 | $6,640,000 |
| Common Stock | $7,354,000 | $7,227,000 | $7,058,000 | $6,640,000 |
| Employee Benefits | $3,093,000 | $1,803,000 | $1,449,000 | $870,000 |
| Long Term Capital Lease Obligation | $36,327,000 | $32,520,000 | $15,354,000 | $9,009,000 |
| Current Capital Lease Obligation | $10,833,000 | $6,533,000 | $4,646,000 | $3,417,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $212,344,000 | $150,818,000 | $95,104,000 | $84,337,000 |
| Current Provisions | $402,032,000 | $140,474,000 | $55,788,000 | $19,478,000 |
| Investments And Advances | $50,530,000 | $49,697,000 | $47,155,000 | $40,481,000 |
| Available For Sale Securities | $10,022,000 | $14,880,000 | $15,528,000 | $17,443,000 |
| Investmentsin Joint Venturesat Cost | $3,378,000 | $9,268,000 | $9,912,000 | $1,323,000 |
| Net PPE | $48,247,000 | $43,518,000 | $22,676,000 | $16,235,000 |
| Accumulated Depreciation | $-35,722,000 | $-29,198,000 | $-22,675,000 | $-18,047,000 |
| Gross PPE | $83,969,000 | $72,716,000 | $45,351,000 | $34,282,000 |
| Leases | $7,489,000 | $2,957,000 | $1,975,000 | $1,981,000 |
| Other Properties | $346,000 | $346,000 | $346,000 | $346,000 |
| Machinery Furniture Equipment | $29,221,000 | $20,423,000 | $14,445,000 | $12,140,000 |
| Buildings And Improvements | $46,913,000 | $48,990,000 | $28,585,000 | $19,815,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $82,455,000 | $43,044,000 | $22,640,000 | $37,291,000 |
| Work In Process | $55,535,000 | $26,357,000 | $47,074,000 | $65,016,000 |
| Raw Materials | $335,540,000 | $337,832,000 | $240,836,000 | $126,046,000 |
| Other Short Term Investments | $948,750,000 | $1,878,890,000 | $1,131,000,000 | $1,391,808,000 |
| Current Accrued Expenses | - | - | $55,788,000 | $19,478,000 |
| Non Current Deferred Revenue | - | - | - | $0 |
| Current Deferred Revenue | - | - | - | $0 |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $573,512,000 | $-151,048,000 | $-464,139,000 | $-966,630,000 |
| Operating Activities | ||||
| Operating Cash Flow | $685,192,000 | $-82,747,000 | $-420,327,000 | $-862,807,000 |
| Cash Flow From Continuing Operating Activities | $685,192,000 | $-82,747,000 | $-420,327,000 | $-862,807,000 |
| Operating Gains Losses | $13,541,000 | $8,076,000 | $4,984,000 | $1,136,000 |
| Investing Activities | ||||
| Capital Expenditure | $-111,680,000 | $-68,301,000 | $-43,812,000 | $-103,823,000 |
| Investing Cash Flow | $984,005,000 | $-717,594,000 | $308,210,000 | $-461,184,000 |
| Cash Flow From Continuing Investing Activities | $984,005,000 | $-717,594,000 | $308,210,000 | $-461,183,000 |
| Net Other Investing Changes | - | - | - | $-1,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $1,196,731,000 | $760,953,000 |
| Financing Cash Flow | $233,010,000 | $279,759,000 | $1,336,727,000 | $843,757,000 |
| Cash Flow From Continuing Financing Activities | $233,010,000 | $279,759,000 | $1,336,727,000 | $843,757,000 |
| Net Other Financing Charges | $-41,258,000 | $-21,868,000 | $-14,466,000 | $-6,226,000 |
| Net Common Stock Issuance | $0 | $0 | $1,196,731,000 | $760,953,000 |
| Common Stock Issuance | $0 | $0 | $1,196,731,000 | $760,953,000 |
| Other | ||||
| Repayment Of Debt | $-4,107,000 | $-7,638,000 | $-3,801,000 | $-4,165,000 |
| End Cash Position | $3,491,289,000 | $1,499,936,000 | $2,048,844,000 | $800,740,000 |
| Beginning Cash Position | $1,499,936,000 | $2,048,844,000 | $800,740,000 | $1,334,676,000 |
| Effect Of Exchange Rate Changes | $89,146,000 | $-28,326,000 | $23,494,000 | $-53,702,000 |
| Changes In Cash | $1,902,207,000 | $-520,582,000 | $1,224,610,000 | $-480,234,000 |
| Proceeds From Stock Option Exercised | $278,375,000 | $309,265,000 | $158,263,000 | $93,195,000 |
| Net Issuance Payments Of Debt | $-4,107,000 | $-7,638,000 | $-3,801,000 | $-4,165,000 |
| Net Long Term Debt Issuance | $-4,107,000 | $-7,638,000 | $-3,801,000 | $-4,165,000 |
| Long Term Debt Payments | $-4,107,000 | $-7,638,000 | $-3,801,000 | $-4,165,000 |
| Interest Received Cfi | $162,670,000 | $111,649,000 | $92,753,000 | $13,146,000 |
| Net Investment Purchase And Sale | $939,515,000 | $-753,942,000 | $272,269,000 | $-368,506,000 |
| Sale Of Investment | $2,388,445,000 | $1,429,600,000 | $1,543,999,000 | $1,325,540,000 |
| Purchase Of Investment | $-1,448,930,000 | $-2,183,542,000 | $-1,271,730,000 | $-1,694,046,000 |
| Net Business Purchase And Sale | $-6,500,000 | $-7,000,000 | $-13,000,000 | $-2,000,000 |
| Purchase Of Business | $-6,500,000 | $-7,000,000 | $-13,000,000 | $-2,000,000 |
| Net Intangibles Purchase And Sale | $-105,515,000 | $-66,500,000 | $-43,000,000 | $-102,986,000 |
| Purchase Of Intangibles | $-105,515,000 | $-66,500,000 | $-43,000,000 | $-102,986,000 |
| Net PPE Purchase And Sale | $-6,165,000 | $-1,801,000 | $-812,000 | $-837,000 |
| Purchase Of PPE | $-6,165,000 | $-1,801,000 | $-812,000 | $-837,000 |
| Taxes Refund Paid | $-254,855,000 | $7,801,000 | $-37,515,000 | $-24,141,000 |
| Interest Paid Cfo | $-900,000 | $-392,000 | $-211,000 | $-851,000 |
| Change In Working Capital | $-422,628,000 | $-325,173,000 | $-308,891,000 | $-375,722,000 |
| Change In Other Current Assets | $8,482,000 | $-21,971,000 | $-30,359,000 | $-34,514,000 |
| Change In Payables And Accrued Expense | $612,328,000 | $246,336,000 | $95,600,000 | $329,000 |
| Change In Payable | $612,328,000 | $246,336,000 | $95,600,000 | $329,000 |
| Change In Prepaid Assets | $-142,159,000 | $-30,430,000 | $-105,408,000 | $0 |
| Change In Inventory | $-98,952,000 | $-95,996,000 | $-83,030,000 | $-119,277,000 |
| Change In Receivables | $-802,327,000 | $-423,112,000 | $-185,694,000 | $-222,260,000 |
| Other Non Cash Items | $31,628,000 | $-277,000 | $2,074,000 | - |
| Stock Based Compensation | $248,079,000 | $235,179,000 | $232,974,000 | $157,026,000 |
| Unrealized Gain Loss On Investment Securities | $-11,581,000 | $-3,834,000 | $0 | $-4,256,000 |
| Depreciation Amortization Depletion | $28,102,000 | $17,527,000 | $111,307,000 | $104,342,000 |
| Depreciation And Amortization | $28,102,000 | $17,527,000 | $111,307,000 | $104,342,000 |
| Amortization Cash Flow | $14,858,000 | $10,282,000 | $105,674,000 | $99,766,000 |
| Amortization Of Intangibles | $14,858,000 | $10,282,000 | $105,674,000 | $99,766,000 |
| Depreciation | $13,244,000 | $7,245,000 | $5,633,000 | $4,576,000 |
| Pension And Employee Benefit Expense | $1,151,000 | $432,000 | $573,000 | $459,000 |
| Earnings Losses From Equity Investments | $12,390,000 | $7,644,000 | $4,411,000 | $677,000 |
| Net Income From Continuing Operations | $1,053,806,000 | $-21,654,000 | $-425,049,000 | $-720,341,000 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-11